| Interconnected microphysiological systems for quantitative biology and pharmacology studies CD Edington, WLK Chen, E Geishecker, T Kassis, LR Soenksen, ... Scientific reports 8 (1), 4530, 2018 | 433 | 2018 |
| Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model JH Sung‡, J Yu‡, D Luo, ML Shuler, JC March Lab on a Chip 11 (3), 389-392, 2011 | 372 | 2011 |
| On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’devices MB Esch, JH Sung, J Yang, C Yu, J Yu, JC March, ML Shuler Biomedical microdevices 14, 895-906, 2012 | 209 | 2012 |
| Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk WLK Chen, C Edington, E Suter, J Yu, JJ Velazquez, JG Velazquez, ... Biotechnology and bioengineering 114 (11), 2648-2659, 2017 | 170 | 2017 |
| In vitro 3D human small intestinal villous model for drug permeability determination J Yu, S Peng, D Luo, JC March Biotechnology and bioengineering 109 (9), 2173-2178, 2012 | 169 | 2012 |
| Synthetic small intestinal scaffolds for improved studies of intestinal differentiation CM Costello, J Hongpeng, S Shaffiey, J Yu, NK Jain, D Hackam, ... Biotechnology and bioengineering 111 (6), 1222-1232, 2014 | 155 | 2014 |
| Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System U Sarkar, KC Ravindra, E Large, CL Young, D Rivera-Burgos, J Yu, ... Drug Metabolism and Disposition 45 (7), 855-866, 2017 | 70 | 2017 |
| Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer YC Chen, J Yu, C Metcalfe, T De Bruyn, T Gelzleichter, V Malhi, ... Expert Opinion on Investigational Drugs, 1-15, 2021 | 55 | 2021 |
| Three dimensional human small intestine models for ADME-Tox studies J Yu, RL Carrier, JC March, LG Griffith Drug discovery today 19 (10), 1587-1594, 2014 | 54 | 2014 |
| Quantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi‐MPS Integration J Yu, NA Cilfone, EM Large, U Sarkar, JS Wishnok, SR Tannenbaum, ... CPT: Pharmacometrics & Systems Pharmacology 4 (10), 585-594, 2015 | 52 | 2015 |
| Clinical pharmacology perspectives for adoptive cell therapies in oncology W Huang, J Li, MZ Liao, SN Liu, J Yu, J Jing, N Kotani, L Kamen, ... Clinical Pharmacology & Therapeutics 112 (5), 968-981, 2022 | 15 | 2022 |
| Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis P Chan, J Yu, L Chinn, M Prohn, J Huisman, B Matzuka, W Hanley, ... Pharmaceutical Research 37 (2), 25, 2020 | 15 | 2020 |
| A new method to model and predict progression free survival based on tumor growth dynamics J Yu, N Wang, M Kågedal CPT: Pharmacometrics & Systems Pharmacology 9 (3), 177-184, 2020 | 13 | 2020 |
| Phase Ia/b Study of Giredestrant±Palbociclib and±Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast … KL Jhaveri, M Bellet, NC Turner, S Loi, A Bardia, V Boni, J Sohn, ... Clinical Cancer Research 30 (4), 754-766, 2024 | 5 | 2024 |
| Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer V Malhi, P Agarwal, MR Gates, L Liu, J Wang, T De Bruyn, S Lam, ... Cancer Research Communications 3 (12), 2551-2559, 2023 | 2 | 2023 |
| Fenebrutinib, a noncovalent, highly selective, long residence time investigational btk inhibitor for the treatment of ms A Johnson, C Harp, J Yu, A Goodyear, J Crawford MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 283-283, 2020 | 2 | 2020 |
| Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes L Brooks, M Dolton, J Langenhorst, K Yoshida, YT Lien, V Malhi, C Li, ... Clinical and Translational Science 16 (5), 823-834, 2023 | 1 | 2023 |
| Abstract PO4-04-11: Exposure–response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic … K Jhaveri, YT Lien, N Turner, E Lim, M Cannon, R Anziano, J Langenhorst, ... Cancer Research 84 (9_Supplement), PO4-04-11-PO4-04-11, 2024 | | 2024 |
| A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy … Y Xu, D Kuruvilla, JN Ratchford, Q Qi, L Pan, J Yu Neurology 102 (17_supplement_1), 3656, 2024 | | 2024 |
| UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure V Malhi, M Nowicka, YC Chen, P Agarwal, M Waldvogel, YTK Lien, ... Cancer Chemotherapy and Pharmacology, 1-6, 2024 | | 2024 |
